Loss of ARID1A expression leads to sensitivity to ROS-inducing agent elesclomol in gynecologic cancer cells

Inactivating mutations in ARID1A are found in a broad spectrum of cancer types, with the highest frequency in gynecologic cancers. However, therapeutic strategies targeting ARID1A-mutant cancer cells remain limited. In this study, we aimed to identify drugs sensitivities in ARID1A-mutant cancer cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwan, Suet-Yan, Cheng, Xuanjin, Tsang, Yvonne T.M., Choi, Jong-Sun, Kwan, Suet-Ying, Izaguirre, Daisy I., Kwan, Hoi-Shan, Gershenson, David M., Wong, Kwong-Kwok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302963/
https://www.ncbi.nlm.nih.gov/pubmed/27486766
http://dx.doi.org/10.18632/oncotarget.10921

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302963/
https://www.ncbi.nlm.nih.gov/pubmed/27486766
http://dx.doi.org/10.18632/oncotarget.10921

Ejemplares similares